GemVax & KAEL (082270) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, GemVax & KAEL (082270) reported revenue of 81.5 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202581.5 billion KRW3.8 billion KRW-11.3 billion KRW[source]
202462.7 billion KRW-38.3 billion KRW-87.2 billion KRW[source]
202372.2 billion KRW-7.9 billion KRW-27.2 billion KRW[source]
202275.8 billion KRW-3.9 billion KRW-19.6 billion KRW[source]
202160.4 billion KRW-3.6 billion KRW12.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025164.0 billion KRW101.7 billion KRW62.4 billion KRW[source]
2024161.7 billion KRW121.7 billion KRW40.0 billion KRW[source]
2023143.1 billion KRW27.1 billion KRW116.0 billion KRW[source]
2022152.3 billion KRW16.8 billion KRW135.6 billion KRW[source]
2021182.4 billion KRW18.3 billion KRW164.1 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice